William B Isaacs

US Patent:

7008765, Mar 7, 2006

Filed:

Apr 9, 1998

Appl. No.:

09/402713

Inventors:

Marion J. G. Bussemakers - Nijmegen, NL
William B. Isaacs - Glyndon MD, US

Assignee:

The Johns Hopkins University - Baltimore MD
Stichting Katholieke Universiteit more particularly The University Medical Centre - Nijmegen

International Classification:

C12Q 1/68
C07H 21/04
C12N 15/11
C12N 15/63

US Classification:

435 6, 536 231, 536 234, 536 2431, 4353201

Abstract:

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

US Patent:

7579147, Aug 25, 2009

Filed:

Apr 30, 2003

Appl. No.:

10/426262

Inventors:

Jianfeng Xu - Clemmons NC, US
Deborah Meyers - Mocksville NC, US
Sigun Zheng - Clemmons NC, US
Patrick C. Walsh - Hunt Valley MD, US
William B. Isaacs - Glyndon MD, US
Eugene Bleecker - Winston-Salem NC, US
David Herrington - Winston Salem NC, US

Assignee:

Wake Forest University Health Sciences - Winston-Salem NC

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.

US Patent:

7632643, Dec 15, 2009

Filed:

Oct 28, 2005

Appl. No.:

11/260282

Inventors:

Marion J. G. Bussemakers - Nijmegen, NL
William B. Isaacs - Glyndon MD, US

Assignee:

Stichting Katholieke Universiteit, More Particularly the University Medical Centre Nijmegen - Nijmegen
The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

US Patent:

8192928, Jun 5, 2012

Filed:

Jul 16, 2009

Appl. No.:

12/504034

Inventors:

Jianfeng Xu - Clemmons NC, US
Deborah Meyers - Mocksville NC, US
Sigun Zheng - Clemmons NC, US
Patrick C. Walsh - Hunt Valley MD, US
William B. Isaacs - Glyndon MD, US
Eugene Bleecker - Winston-Salem NC, US
David Herrington - Winston Salem NC, US

Assignee:

Wake Forest University Health Sciences - Winston-Salem NC

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.

US Patent:

8551699, Oct 8, 2013

Filed:

Oct 30, 2009

Appl. No.:

12/609483

Inventors:

Marion J. G. Bussemakers - Nijmegen, NL
William B. Isaacs - Glyndon MD, US

Assignee:

Stichting Katholieke Universiteit, more particularly The University of Medical Centre Nijmegen - Nijmegen
The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 61, 435 611, 435 612, 435 614

Abstract:

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

US Patent:

20090226912, Sep 10, 2009

Filed:

Dec 19, 2008

Appl. No.:

12/339653

Inventors:

Jianfeng Xu - Clemmons NC, US
S. Lilly Zheng - Clemmons NC, US
Henrik Gronberg - Stockholm, SE
William B. Isaacs - Glyndon MD, US

International Classification:

C12Q 1/68
G06F 17/30

US Classification:

435 6, 707 3, 707E17014, 707E17044

Abstract:

The present invention provides a method of identifying a subject as having an increased risk of developing prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of developing prostate cancer.

US Patent:

20110110926, May 12, 2011

Filed:

Apr 16, 2009

Appl. No.:

12/988299

Inventors:

Jun Luo - Clarksville MD, US
George Steven Bova - Baltimore MD, US
William Isaacs - Glyndon MD, US
Thomas Dunn - Baltimore MD, US
Rong Hu - Catonsville MD, US

Assignee:

Johns Hopkins University - Baltimore MD

International Classification:

A61K 39/395
C07K 16/18
C07K 14/00
C07H 21/00
C07H 21/02
C12N 5/10
C40B 40/06
C12Q 1/68
G01N 33/53
C40B 30/04
A61K 31/7088
A61K 31/7105
A61K 31/713
A61P 35/00

US Classification:

4241301, 5303897, 530324, 536 235, 536 231, 4353201, 435325, 536 245, 506 16, 435 6, 435 721, 435 71, 506 9, 514 44 A, 514 44 R

Abstract:

The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.

US Patent:

20120178082, Jul 12, 2012

Filed:

Jan 6, 2012

Appl. No.:

13/344907

Inventors:

Jianfeng Xu - Clemmons NC, US
William B. Isaacs - Glyndon MD, US
Henrik Grönberg - Stockholm, SE

International Classification:

C12Q 1/68
H01J 49/40
G06F 17/30

US Classification:

435 611, 707740, 250282, 707E17005, 707E17014

Abstract:

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.